Article
Pharmacological management of heart failure: treat early and treat fast
- Aust Prescr 2026;49:225-34
- 1 December 2026
- DOI: 10.18773/austprescr.2026.056


Heart failure management is determined by left ventricular ejection fraction, distinguishing between preserved and reduced ejection fraction phenotypes.
The 4 pillars of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF) are renin–angiotensin–aldosterone system inhibitors, beta blockers, mineralocorticoid receptor antagonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Pharmacological treatment of heart failure with preserved ejection fraction (HFpEF) centres on SGLT2 inhibitors and mineralocorticoid receptor antagonists, with additional therapies guided by the patient’s symptoms and comorbidities.
Early optimisation of guideline-directed medical therapy reduces mortality and heart failure hospitalisations. Structured multidisciplinary follow-up is essential to achieve optimal patient outcomes.
Heart failure (HF) is a clinical syndrome with typical symptoms and signs, including dyspnoea and fatigue, that generally occur on exertion but can also occur at rest, particularly when recumbent. These symptoms arise from abnormalities in cardiac structure or function that impair ventricular filling or ejection.1
Investigations for underlying causes of HF should be undertaken at diagnosis, and these conditions should be managed alongside HF-specific pharmacotherapy.1 Some causes of HF, such as cardiac amyloidosis and hypertrophic cardiomyopathy, require treatment that differs from the standard approach.
The prevalence of HF in Australia is growing, affecting at least 2% of adults, and it remains a leading cause of hospitalisation.2 Pharmacological therapy has substantially improved outcomes, and chronic ambulatory HF now has an estimated 1-year survival rate of 87% and a 5-year survival rate of 60%.3
Guideline-directed medical therapy (GDMT), also known as foundational medical therapy, involves multiple classes of drugs that target neurohormonal pathways that contribute to disease progression. Classification of HF by left ventricular ejection fraction (LVEF) guides the treatment algorithm. The most important shift in treatment has been from the sequential introduction of medications to the early initiation of all 4 pillars of disease-modifying therapy in HF with reduced ejection fraction (HFrEF). GDMT should be optimised wherever possible, and treatment should be individualised, particularly in older adults and those with frailty or multimorbidity, where a more tailored approach may be required to minimise harm. Additional drug therapies may be added as indicated. GDMT for HF with preserved ejection fraction (HFpEF) is more limited.
This article reviews contemporary pharmacological management of HF in Australian clinical practice.
Australian guidelines classify HFrEF as LVEF less than 50% and HFpEF as LVEF 50% or greater.1
The 2026 European Society of Cardiology (ESC) guidelines have adopted a similar classification,4 with HFpEF additionally requiring objective evidence of cardiac structural or functional abnormalities consistent with elevated filling pressures. Importantly, the ESC guidelines have removed HF with mildly reduced ejection fraction (HFmrEF) as a separate phenotype, recognising that a single LVEF threshold is an imperfect discriminator and that LVEF should be interpreted in the clinical context.
One further category is HF with improved ejection fraction (HFimpEF), in which a previously reduced LVEF has increased or normalised. HFimpEF reflects improvement in EF but not resolution of the underlying cardiomyopathy. In most cases, HFimpEF is treated the same as HFrEF, requiring lifelong continuation of GDMT because treatment withdrawal can precipitate relapse.5
GDMT for patients with HFrEF are known as ‘the 4 pillars’ (Table 1). These are:
| Drug class | Mechanism of action | Adverse effects | Drug | Starting dose | Target dose | Titration | Key monitoring |
| RAAS inhibitors | |||||||
|
ARNI |
Causes vasodilation Reduces sympathetic activity Enhances diuresis |
Angioedema Hypotension |
Sacubitril with valsartan |
24 mg sacubitril with 26 mg valsartan twice daily |
97 mg sacubitril with 103 mg valsartan twice daily |
Double dose every 2 to 4 weeks |
Blood pressure: do not increase dose if there is symptomatic hypotension. If there is asymptomatic hypotension, continue dose and repeat blood pressure measurement within 1 week Bloods: check renal function and potassium within 2 weeks of a dose change and every 6 to 12 months when dose is stable If eGFR declines by more than 30%, assess volume status, review other contributors (e.g. diuretics, NSAIDs) and, if no other contributors, reduce dose and repeat in 1 to 2 weeks If potassium is greater than 5.5 mmol/L, assess volume status, ensure no potassium supplementation and, if not successful, reduce dose or stop MRA and/or RAAS inhibitor |
|
ACEi |
Reduce vasoconstriction, sodium reabsorption and aldosterone secretion |
Hypotension Worsening renal function Hyperkalaemia Chronic cough Angioedema |
Ramipril |
1.25 to 2.5 mg daily |
10 mg daily |
Increase dose every 1 to 2 weeks |
|
|
Perindopril erbumine |
2 mg daily |
8 mg daily |
Increase dose every 1 to 2 weeks |
||||
|
Perindopril arginine |
2.5 mg daily |
10 mg daily |
Increase dose every 1 to 2 weeks |
||||
|
ARBs If ACEi intolerant |
Reduce vasoconstriction, sodium reabsorption and aldosterone secretion |
Hypotension Worsening renal function Hyperkalaemia |
Candesartan [NB1] |
4 mg daily |
32 mg daily |
Double dose every 2 weeks |
|
|
Valsartan [NB1] |
40 mg twice daily |
160 mg twice daily |
Increase dose every 1 to 2 weeks |
||||
| Heart failure–specific beta blockers | |||||||
|
Beta blockers |
Reduce sympathetic activity Antiarrhythmic effects Reverse remodelling |
Hypotension Bradycardia Fatigue Bronchospasm Impotence Worsening heart failure in congested patients Masking of hypoglycaemia symptoms |
Bisoprolol |
1.25 mg daily |
10 mg daily |
Double dose every 2 weeks |
Heart rate: continue therapy if asymptomatic bradycardia (heart rate 50 to 60 beats per minute). If symptomatic bradycardia (heart rate below 50 beats per minute), arrange an ECG to document rhythm, review any other rate-lowering drugs and, if not successful, reduce dose of beta blocker Blood pressure: continue therapy unless symptomatic hypotension not responsive to RAAS inhibitor changes OR evidence of shock Congestion: do not increase dose if present |
|
Metoprolol succinate |
23.75 mg daily |
190 mg daily |
Double dose every 2 weeks |
||||
|
Carvedilol |
3.125 mg twice daily |
25 mg twice daily |
Double dose every 2 weeks |
||||
|
Nebivolol |
1.25 mg daily |
10 mg daily |
Double dose every 2 weeks |
||||
| MRAs | |||||||
|
MRAs |
Weak diuretic effect Reduce effects of aldosterone |
Hyperkalaemia Worsening renal function Hypotension Gynaecomastia (spironolactone) |
Spironolactone |
25 mg daily |
25 to 50 mg daily (25 mg daily is usually sufficient) |
Increase dose after 4 weeks if potassium concentration is 5.0 mmol/L or less and renal function is stable (eGFR decline less than 30%) |
Blood pressure: only stop if symptomatic hypotension not responsive to changes with ARNI (or ACEi or ARB) and beta blocker Bloods: check potassium and renal function 3 to 7 days after initiation, then every 4 weeks for 3 months, then every 3 to 6 months |
|
Eplerenone |
25 mg daily |
50 mg daily (25 mg is usually sufficient) |
|||||
| SGLT2 inhibitors | |||||||
|
SGLT2 inhibitors |
Osmotic diuresis and natriuresis Improve cardiac metabolism Reduce myocardial fibrosis and inflammation |
Euglycaemic ketoacidosis Hypotension Genitourinary infections |
Dapagliflozin |
10 mg daily |
10 mg daily |
No titration |
Renal function: can tolerate up to 30% decline in eGFR in the first month of treatment Volume status |
|
Empagliflozin |
10 mg daily |
10 mg daily |
No titration |
||||
| ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor–neprilysin inhibitor; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate; HFrEF = heart failure with reduced ejection fraction, MRAs = mineralocorticoid receptor antagonists; NSAIDs = nonsteroidal anti-inflammatory drugs; RAAS = renin–angiotensin–aldosterone system; SGLT2 = sodium-glucose co-transporter 2 NB1: Candesartan and valsartan are the ARBs with the strongest trial outcome evidence in heart failure. | |||||||
Each drug class targets a different pathophysiological pathway, and the benefits of each class are independent and additive. The combination of all 4 pillars has been associated with an approximate 60% relative reduction in all-cause mortality compared with no therapy in modelling analyses, which translates to an approximate 5.3 additional years of life in an individual aged 70 years old.6
Rather than maximising one drug before starting another, current practice is for all 4 pillars to be initiated early, with sequential introduction and rapid up-titration according to the patient’s clinical status. Simultaneous initiation may be appropriate in select patients, particularly in hospital. Clinical benefits are seen with subtarget doses, and delays in initiation increase the morbidity and mortality of patients with HFrEF.7
Among renin–angiotensin–aldosterone system inhibitors, an ARNI (sacubitril with valsartan) is recommended as first-line therapy in ambulatory patients, having been shown to reduce the composite outcome of cardiovascular death or HF hospitalisation by 20% compared with enalapril,8,9 in addition to the established mortality benefit of ACEi (approximately 20%) over placebo.10 However, in Australia, the subsidised use of an ARNI through the Pharmaceutical Benefits Scheme (PBS) requires prior stabilisation on an ACEi or ARB. Starting an ARB first allows an easier switch to ARNI, whereas an ACEi requires a 36-hour washout after the last ACEi dose because of the increased risk of angioedema. If an ARNI is contraindicated, an ACEi or ARB may be used long term.
HF-specific beta blockers (bisoprolol, metoprolol succinate, carvedilol and nebivolol) reduce mortality and HF hospitalisation by approximately 30 to 35% in patients with HFrEF compared with placebo.11 They should only be initiated or up-titrated when the patient is euvolaemic because beta blockers can precipitate decompensation in patients with congestion.
MRAs (spironolactone and eplerenone) reduce mortality and HF hospitalisation by approximately 30% compared with placebo.12 They can cause hyperkalaemia, so serum electrolytes and renal function must be monitored after initiation and dose titration. MRAs are generally avoided if the estimated glomerular filtration rate (eGFR) is less than 30 mL/min/1.73 m2; however, they can be continued at a reduced dose if the eGFR is 25 to 30 mL/min/1.73 m2. MRAs have traditionally been avoided if potassium concentrations cannot be maintained below 5.5 mmol/L; however, potassium-lowering drugs, including patiromer (PBS-subsidised) and sodium zirconium cyclosilicate, can facilitate continued MRA use in patients with chronic hyperkalaemia and chronic kidney disease.13 Eplerenone (PBS-subsidised) is an alternative to spironolactone if gynaecomastia develops.
In HFrEF, SGLT2 inhibitors (dapagliflozin and empagliflozin) reduce the composite outcome of HF hospitalisations and cardiovascular death by approximately 25%, with the benefit predominantly driven by reductions in HF hospitalisations. They also improve symptoms and quality of life.14,15 SGLT2 inhibitors can be initiated at an eGFR greater than 25 mL/min/1.73 m2 for dapagliflozin and greater than 20 mL/min/1.73 m2 for empagliflozin. A mild transient decline in eGFR (typically 10 to 30%) may occur after initiation and does not require treatment cessation. Despite this initial decline in eGFR, SGLT2 inhibitors are associated with a slower long-term decline in renal function compared with placebo.16 A larger or progressive decline in renal function should prompt assessment for other causes and consideration of whether treatment should be continued. Patients should be advised about the risk of genitourinary infections and to temporarily stop SGLT2 inhibitors during acute illness or fasting because of the risk of euglycaemic ketoacidosis.
All 4 pillars should ideally be initiated within 4 weeks of diagnosis, with titration towards target or maximum tolerated doses over approximately 6 weeks. Starting low doses of all 4 pillars is preferable to using full doses of fewer medications.7 The STRONG-HF trial showed that titration to target doses within 2 to 3 weeks is feasible and safe and reduces the risk of HF readmission or death at 180 days compared with usual care.17 These findings support early, structured post-diagnosis follow-up, with medication up-titration every 1 to 2 weeks (Table 2). This approach should be individualised in older patients and those with frailty, chronic kidney disease or recurrent decompensations. Multidisciplinary HF programs, including nurse- or pharmacist-led titration, improve attainment of target doses, reduce hospitalisations and improve quality of life.18
Table 2 Structured GDMT up-titration plan for patients with HFrEF, based on the STRONG-HF trial17
| Time point | Actions | Monitoring checklist for each visit | Safety thresholds for adjustment |
|
Week 1 |
Initiate all 4 pillars:
|
HF Symptoms: dyspnoea, orthopnoea, fatigue HF Signs: weight, oedema, blood pressure, heart rate Laboratory results: urea, electrolytes (sodium, potassium), creatinine (eGFR) Treatment Adherence Adverse effects Also provide HF education |
Do not up-titrate ARNI (or ACEi or ARB) or MRA if any of the following are present:
Do not up-titrate beta blocker if any of the following are present:
|
|
Week 1 to 2 |
Increase dose of 1 to 2 drugs and add in remaining pillars if not already initiated Adjust diuretics |
||
|
Week 2 to 3 |
Up-titrate remaining drugs Adjust diuretics |
||
|
Week 3 to 4 |
Reach target or maximum tolerated doses |
||
|
Week 6 |
Stabilisation review Fine-tune doses |
||
|
Week 12 |
Maintain maximum tolerated doses |
||
| ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor–neprilysin inhibitor; eGFR = estimated glomerular filtration rate; GDMT = guideline-directed medical therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; SGLT2 = sodium-glucose co-transporter 2 | |||
A consensus Australian approach to initiating the 4 pillars is outlined in Figure 1.8 If congestion is present, an ARNI (or ACEi or ARB) and an SGLT2 inhibitor should be started first, followed by an MRA. Once the patient is euvolaemic, an HF-specific beta blocker should be added. If euvolaemic, an ARNI (or ACEi or ARB) and beta blocker can be started first, followed by an MRA and SGLT2 inhibitor.
Flow chart outlining the Australian consensus approach to up-titration of guideline-directed medical therapy (GDMT) in heart failure with reduced ejection fraction. If congestion is present, initiate diuretic therapy until euvolaemia is achieved, then reduce diuretics to the lowest effective dose. Start GDMT with an ARNI (or ACEi or ARB) and an SGLT2 inhibitor, followed by an MRA. Add a heart failure–specific beta blocker once the patient is euvolaemic. If the patient is already euvolaemic, start an ARNI (or ACEi or ARB) and beta blocker first, followed by an MRA and SGLT2 inhibitor. Up-titrate GDMT to the maximum tolerated doses, preferentially increasing the beta blocker dose unless congestion is present or the heart rate is below 50 beats per minute.
For maximum therapeutic benefits, each drug should be titrated to the target dose, ideally within 6 weeks (Table 1). Clinical review should occur 1 to 2 weeks after each dose change. If there is a decline in eGFR of more than 30%, medications and fluid status should be reassessed. Asymptomatic hypotension is acceptable during up-titration, usually if systolic blood pressure remains at least 90 mmHg. However, symptomatic hypotension warrants prompt review. If the patient appears hypovolaemic, consider reducing the diuretic dose, reducing vasodilators and splitting doses of ACEi, ARB or beta blockers before reducing GDMT. In patients with no cardiac device in situ whose heart rate is below 50 beats per minute while taking a beta blocker, the beta blocker dose may need to be reduced.
Older age and frailty are not contraindications to GDMT, but adverse effects such as hypotension, dizziness and falls may occur during up-titration, so treatment should be individualised.19 Treatment should be initiated at low doses and up-titrated slowly. GDMT should not be withheld or underused because mortality and quality of life benefits are maintained in these patients.
HFpEF is characterised by diastolic dysfunction, in which the left ventricle is unable to relax adequately during filling. This leads to elevated filling pressures, particularly on exertion, resulting in exertional dyspnoea.20 Older age and female sex are major risk factors, along with cardiometabolic conditions including obesity, diabetes, hypertension, chronic kidney disease, atrial fibrillation and sleep-disordered breathing. Pharmacological treatment of HFpEF is centred on SGLT2 inhibitors and MRAs, with loop diuretics used to manage congestion and additional therapies tailored to the patient and their comorbidities (Table 3).21
| Drug class | Mechanism of action | Adverse effects | Drug | Starting dose | Target dose | Titration | Key monitoring |
|
SGLT2 inhibitors |
Osmotic diuresis and natriuresis Improve cardiac metabolism Reduce myocardial fibrosis and inflammation |
Euglycaemic ketoacidosis Hypotension Genitourinary infections |
Dapagliflozin |
10 mg daily |
10 mg daily |
No titration |
Renal function: can tolerate up to 30% decline in eGFR in the first month of treatment Volume status |
|
Empagliflozin |
10 mg daily |
10 mg daily |
No titration |
||||
|
Nonsteroidal MRA |
Reduces effects of aldosterone |
Worsening renal function Hypotension Hyperkalaemia (lower risk than spironolactone) |
Finerenone |
20 mg daily if eGFR 60 mL/min/1.73 m2 or greater 10 mg daily if eGFR 25 to 59 mL/min/1.73 m2 |
40 mg daily if eGFR 60 mL/min/1.73 m2 or greater 20 mg daily if eGFR 25 to 59 mL/min/1.73 m2 |
Increase dose after 4 weeks if potassium is 5.0 mmol/L or less and eGFR has not declined by more than 30% from previous measurement Do not change dose if potassium is greater than 5.0 mmol/L but less than 5.5 mmol/L, or if eGFR declines more than 30% Halve dose if potassium is greater than 5.5 mmol/L (or withhold if on 10 mg dose) and restart at lower dose once potassium is less than 5.5 mmol/L |
Blood pressure: only stop if symptomatic hypotension is not responsive to changes with antihypertensive therapy Bloods: check potassium and renal function 3 to 7 days after initiation or dose increase, then every 4 weeks for 3 months, then every 3 to 6 months Volume status |
|
MRA |
Weak diuretic Reduces effects of aldosterone |
Hyperkalaemia Worsening renal function Hypotension Gynaecomastia |
Spironolactone |
25 mg daily |
25 to 50 mg daily |
Increase dose after 4 weeks if 5.0 mmol/L or less and eGFR has not declined by more than 30% |
Blood pressure: only stop if symptomatic hypotension not responsive to changes with ARNI (or ACEi or ARB) and beta blocker Bloods: check potassium and renal function 3 to 7 days after initiation, then every 4 weeks for 3 months, then every 3 to 6 months |
|
Loop diuretic |
Reduces sodium and water retention |
Renal dysfunction Hypokalaemia Worsened gout Hypotension |
Furosemide |
20 to 40 mg once or twice daily |
– |
Titrate depending on fluid status to a maintenance dose of 20 to 400 mg daily |
Weight: aim for 0.5 to 1 kg loss per day if congested and titrate dose based on patient’s dry weight Blood pressure: assess volume status and reduce or stop if there are no signs or symptoms of congestion Bloods: renal function, potassium, sodium |
| ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor–neprilysin inhibitor; eGFR = estimated glomerular filtration rate; HFpEF = heart failure with preserved ejection fraction; MRA = mineralocorticoid receptor antagonist; SGLT2 = sodium-glucose co-transporter 2 | |||||||
SGLT2 inhibitors should be initiated in all patients with HFpEF unless contraindicated. SGLT2 inhibitors reduce the composite outcome of cardiovascular death and HF hospitalisation by 20% compared with placebo, primarily through a reduction in HF hospitalisations.14
MRAs reduce the composite outcome of cardiovascular mortality and worsening HF in patients with HFpEF. Finerenone, a nonsteroidal MRA, reduced the composite outcome of total worsening HF events (first or recurrent hospitalisation and urgent visit for HF) and cardiovascular death by 16% compared with placebo in patients with HF with LVEF 40% or greater.22 This benefit was predominantly driven by a reduction in worsening HF events, with no significant reduction in cardiovascular mortality. Serum potassium and renal function should be monitored because of the risk of hyperkalaemia (Table 3). Because finerenone is nonsteroidal, it has a lower incidence of gynaecomastia than spironolactone. Finerenone should not be combined with other MRAs, including spironolactone or eplerenone, because of the risk of hyperkalaemia. Spironolactone may be considered in patients with HFpEF to reduce the risk of HF hospitalisation, although it did not significantly reduce the primary composite outcome in the TOPCAT trial.23
In HFpEF, ARNI, ACEi and ARBs have not demonstrated the consistent outcome benefits seen with SGLT2 inhibitors and MRAs,24-26 therefore, they are not recommended for routine use in HFpEF. However, they may have a role in select patients, particularly for the treatment of hypertension.
Beta blockers should be avoided in HFpEF unless there is comorbid angina or atrial fibrillation requiring rate control.21
Patients with clinical congestion should receive diuretics to improve symptoms and achieve euvolaemia, regardless of ejection fraction.27 Loop diuretics, such as furosemide, are first-line therapy and should be titrated to effect. In the event of diuretic resistance, a thiazide or thiazide-like diuretic (e.g. hydrochlorothiazide, metolazone) may be added, a strategy known as sequential nephron blockade. This approach should be initiated in hospital or a closely monitored community setting because of the risk of rapid volume depletion, electrolyte disturbance and renal impairment. Once euvolaemia is achieved, diuretics should be reduced to the lowest effective dose to prioritise GDMT. Some patients require ongoing diuretic therapy to maintain euvolaemia.
Intravenous iron has shown benefits in reducing HF hospitalisations and symptoms and increasing exercise capacity in patients with iron deficiency.28 Intravenous iron infusion should be given to iron-deficient patients with symptomatic HFrEF,, with or without anaemia, if ferritin concentrations are less than 100 micrograms/L or if transferrin saturations are below 20% and ferritin concentrations are 100 to 299 micrograms/L. Both ferric carboxymaltose and ferric derisomaltose are PBS-subsidised. Currently there is no established role for intravenous iron in HFpEF.
Oral iron has not been shown to improve symptoms or exercise capacity, and is generally ineffective at replenishing iron stores, in people with HFrEF.29
Incretin-based therapies, such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists, are emerging as a treatment for obesity-related HFpEF. Obesity contributes to HFpEF through increased blood volume, elevated cardiac filling pressures, metabolic stress and systemic inflammation, which promote myocardial fibrosis and stiffness.30
Semaglutide, a GLP-1 receptor agonist, has been shown to improve weight, exercise capacity and quality of life.31 Tirzepatide, a dual GIP/GLP-1 receptor agonist, reduced the composite outcome of cardiovascular death and worsening HF events.32 The role of incretin-based therapies in HFpEF without obesity, and their effects on mortality, are uncertain.
In HFrEF, incretin-based therapies should be used with caution because they may increase heart rate and the risk of decompensation.33
Incretin-based therapies are not currently approved by the Australian Therapeutic Goods Administration for HF, and trials are ongoing to clarify their role in HF management.
Vericiguat is an oral drug that enhances the nitric oxide–cGMP pathway, which is impaired in HF. In patients with HFrEF and recent decompensation, vericiguat reduced the composite outcome of cardiovascular death and HF hospitalisation by 10% compared with placebo.34 Vericiguat is PBS-subsidised for patients stabilised following a recent HF decompensation requiring hospitalisation or intravenous diuretic therapy who are receiving GDMT.
Ivabradine reduces heart rate and is used in patients with HFrEF who remain tachycardic in sinus rhythm, because elevated heart rate is an independent predictor of cardiovascular morbidity and mortality. Ivabradine has been shown to reduce the composite outcome of cardiovascular death and HF hospitalisation.35 Ivabradine is PBS-subsidised for patients with a heart rate of at least 77 beats per minute in sinus rhythm on maximum tolerated doses of beta blockers.
Digoxin is a cardiac glycoside with positive inotropic and autonomic effects. A 2026 meta-analysis of HFrEF patients demonstrated that cardiac glycosides reduced the risk of the composite outcome of cardiovascular death and worsening HF events, primarily through a reduction in worsening HF events.36 Digoxin may be considered in patients who remain symptomatic despite optimal GDMT when the goal is to reduce the risk of hospitalisation. It should also be considered in patients with HFrEF and atrial fibrillation where additional rate control is required. Digoxin has a narrow therapeutic range and a target trough serum concentration of 0.5 to 0.9 nanograms/mL in HF. The digoxin trough concentration should be measured at steady state, 1 to 2 weeks after initiation or dose change, immediately before the next dose or at least 8 hours after the previous dose.
Hydralazine is an arterial vasodilator and isosorbide dinitrate is predominantly a venodilator. The combination of hydralazine and isosorbide dinitrate may be considered in patients with HFrEF who are intolerant of an ARNI, ACEi or ARB.37
Drugs that worsen HF typically promote fluid retention, increase sympathetic activity or depress myocardial contractility.38 Clinicians should always review new and concomitant drugs when initiating or up-titrating GDMT.
Drugs that promote sodium and fluid retention include nonsteroidal anti-inflammatory drugs (e.g. ibuprofen, celecoxib), corticosteroids (e.g. prednisolone), mineralocorticoids (e.g. fludrocortisone) and thiazolidinediones (e.g. pioglitazone).
Negative inotropes, such as verapamil, diltiazem, sotalol, moxonidine and the antifungal itraconazole, impair myocardial contractility and reduce cardiac output, potentially precipitating hypotension or acute decompensation.
Tricyclic antidepressants (e.g. imipramine, amitriptyline, dosulepin) can cause cardiac conduction abnormalities, including QRS widening, QT prolongation and arrhythmias. Flecainide can worsen HF through negative inotropic effects and cause potentially serious ventricular arrhythmias. Macrolide antibiotics (e.g. clarithromycin, erythromycin) and fluoroquinolones (e.g. ciprofloxacin) can prolong the QT interval and predispose to ventricular arrhythmias.
The management of HF has evolved considerably in recent years, with contemporary evidence-based therapies substantially reducing morbidity and mortality. Accurate classification according to ejection fraction, early initiation and optimisation of GDMT and the use of additional drug therapies to manage symptoms and comorbidities are key to improving outcomes. Effective care requires a multidisciplinary, patient-centred approach, with regular review to optimise treatment and minimise adverse effects.
This article was finalised on 30 October 2026.
Acknowledgements: The authors thank Ms Kellie Easton, Associate Professor Hitesh Patel and Ms Tory Warner for reviewing the initial draft of the manuscript.
Conflicts of interest: Ingrid Hopper has received advisory fees, speaker fees or honoraria from Boehringer Ingelheim, CSL Seqirus, Eli Lilly, Novartis, Novo Nordisk, Viatris and Healthed. Ingrid was an author on the 2018 Australian Heart Failure Guidelines and the 2023 Cardiac Society of Australia and New Zealand’s Expert Position Statement on Catheter and Surgical Ablation for Atrial Fibrillation. Ingrid is a member of the Australian Medicines Handbook board and the Therapeutic Goods Administration Advisory Committee on Medicines. Ingrid was an expert reviewer of heart failure resources for the National Prescribing Curriculum, Medicines Advice Initiative Australia, the NSW Agency for Clinical Innovation, and Veterans’ MATES.
Anna Duggan declared no conflicts of interest.
This article is peer reviewed.
Australian Prescriber welcomes Feedback.
Cardiologist, Metro North Hospital and Health Service, Brisbane
Clinical Pharmacologist and Heart Failure Specialist Physician, The Alfred, Bayside Health, Melbourne
Associate Professor, School of Public Health and Preventive Medicine, Monash University, Melbourne